Literature DB >> 27794456

Infections of the Central Nervous System after Unrelated Donor Umbilical Cord Blood Transplantation or Human Leukocyte Antigen-Matched Sibling Transplantation.

Aitana Balaguer Rosello1, Luis Bataller2, Ignacio Lorenzo3, Isidro Jarque3, Miguel Salavert4, Eva González5, José Luis Piñana3, Teresa Sevilla2, Pau Montesinos3, Gloria Iacoboni3, Nuria Muelas2, Samuel Romero3, Carlos Carretero3, Juan Montoro3, Maria Jose Ibáñez-Juliá2, Guillermo Sanz6, Miguel Ángel Sanz6, Jaime Sanz6.   

Abstract

We analyzed the incidence, clinical characteristics, prognostic factors, and outcome of central nervous system (CNS) infections in consecutive patients with receiving umbilical cord blood transplantation (UCBT) (n = 343) or HLA-matched sibling donor stem cell transplantation (MST) (n = 366). Thirty-four CNS infections were documented at a median time of 116 days after transplantation (range, 7 to 1161). The cumulative incidence (CI) risk of developing a CNS infection was .6% at day +30, 2.3% at day +90, and 4.9% at 5 years. The 5-year CI of CNS infection was 8.2% after UCBT and 1.7% after MST (P < .001). The causative micro-organisms of CNS infections were fungi (35%), virus (32%), Toxoplasma spp. (12%), and bacteria (12%). Fungal infections occurred in 11 patients after UCBT and 1 after MST and were due to Aspergillus spp. (n = 8), Cryptococcus neoformans (n = 2), Scedosporium prolificans (n = 1), and Mucor (n = 1). Except for 1 patient, all died from CNS fungal infection. Viral infections occurred in 9 patients after UCBT and 1 after MST and were due to human herpes virus 6 (n = 7), cytomegalovirus (n = 2), and varicella zoster virus (n = 1). CNS toxoplasmosis was diagnosed in 3 patients after UCBT and 1 after MST. Other pathogens were Staphylococcus spp, Nocardia spp, Streptococcus pneumoniae, and Mycobacterium tuberculosis. Twenty of the 34 patients (59%) died from the CNS infection. In multivariable analysis, UCBT and disease stage beyond first complete remission were independently associated with the risk of developing CNS infections. The 5-year overall survival was 19% in patients who developed a CNS and 39% for those who did not (P = .006). In conclusion, our study showed that CNS infections are a significant clinical problem after stem cell transplantation associated with poor survival. They were more frequent after UCBT compared to MST.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic stem cell transplantation; Encephalitis; Infections; Neurologic complications; Umbilical cord blood

Mesh:

Substances:

Year:  2016        PMID: 27794456     DOI: 10.1016/j.bbmt.2016.10.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  5 in total

1.  Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.

Authors:  Adoración Navarro-Torné; Eva Agostina Montuori; Vasiliki Kossyvaki; Cristina Méndez
Journal:  Hum Vaccin Immunother       Date:  2021-06-09       Impact factor: 4.526

2.  Metagenomic Next-Generation Sequencing vs. Traditional Pathogen Detection in the Diagnosis of Infection After Allogeneic Hematopoietic Stem Cell Transplantation in Children.

Authors:  Yuhua Qu; Wenjiao Ding; Sha Liu; Xiaojing Wang; Pengfei Wang; Haiyan Liu; Han Xia; Yong Chen; Hua Jiang
Journal:  Front Microbiol       Date:  2022-04-18       Impact factor: 5.640

3.  Usefulness of the FilmArray Meningitis/Encephalitis Panel in diagnosis of central nervous system infection after allogeneic hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Yuya Koda; Jun Kato; Masatoshi Sakurai; Yoshifumi Uwamino; Naoki Hasegawa
Journal:  Support Care Cancer       Date:  2021-08-04       Impact factor: 3.603

Review 4.  Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Zhuo Wang; Munan Zhao; Sujun Gao
Journal:  Front Neurol       Date:  2021-07-16       Impact factor: 4.003

5.  Update in Infectious Diseases 2018.

Authors:  F J Candel; T Emilov; I Diaz de la Torre; A Ruedas; J M Viñuela Prieto; C Visiedo; J Martínez-Jordán; L López-González; M Matesanz; A Arribi
Journal:  Rev Esp Quimioter       Date:  2018-09       Impact factor: 1.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.